Danilov Lab
@DanilovLab
Followers
1K
Following
1K
Media
123
Statuses
572
Professor & Director, Early Phase Therapeutics; Co-Director, Lymphoma Center #CLL #lymphoma, translational scientist @cityofhope. Views my own
Los Angeles, CA
Joined May 2021
Great privilege for me and our team Tiana Huynh and Sonia Rodriguez-Rodriguez to speak and represent @cityofhope at @iwCLL in Krakow Poland
1
0
8
Led by @mshadman, we had a wonderful discussion on chronic lymphocytic leukemia with @drjoannarhodes1 and @DanilovLab to wrap up day 1 of #SeattleCT25. Follow for more! @fredhutch @uwmedicine @RutgersCancer @cityofhope #Immunotherapy #ALL #leusm #lymsm #CLLsm #hemepath #MedX
1
4
18
Excited to be part of this group
This Friday and Saturday in Seattle! Take a look at the agenda and the list of speakers! https://t.co/qsMx6gZLMk Looking forward to seeing you all! @binaytara @fredhutch #SeattleCT25
1
1
11
Long overdue publication of our IST of copanlisib-nivo in transformed FL and Richter serving as proof that immunotherapy may make a difference; sustained T cell IFN signaling is predictive of response in RT. Our next Richter project deploys bi-specifics.
10
2
31
Founders of Russian Rock DDT defined the brief era of freedom in Russia in the 90s. Now banned from performing in Russia due to their Mission of PEACE. Amazing sound and poignant lyrics which make you ponder on what is happening to all of us. CLASSIC.
0
0
10
We're thrilled to bring you some fantastic content from #iwCART25!💉🩸 In an exclusive discussion, @KrishPatelMD, @DanilovLab, and @LymphClinician share updates on the progress of #CARTCell therapy & bispecific antibodies in #lymphoma: 🎥 https://t.co/YmGsZ2U7eR
#LYMsm #HemOnc
vjhemonc.com
In this discussion, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, Tycel Phillips, MD, City of Hope, Duarte, CA, and Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, share updates...
0
4
12
At @cityofhope #MCL Program we moved beyond chemotherapy to treat #MCL. Several trials available for newly diagnosed patients: Glofitamab-, Venetoclax- and Nemtabrutinib-based, individualized to patients based on disease genetics, with exciting early data @LymphClinician
1
0
20
Calling pharmacists! Join us at #HemeLA25 on Mar 28-29 to explore novel agents and complex drug interactions for better patient outcomes in hematologic malignancy treatment. Register NOW: https://t.co/aBHqD9ZuTy
#OncPharm #Pharmacy @UCSFCancer @cityofhope @UCDavisHealth
0
1
4
Excited to have @LymphClinician, Dr. Annie Xiao, Dr. Swetha Kambhampati Thiruvengadam of @cityofhope, Dr. Javier Munoz from @MayoClinic, Dr. Naseem Shams Esteghamat (@UCDavisHealth), and @BradHaverkos from @CUCancerCenter to discuss #nonhodgkins #lymphoma at #HemeLA25! Session
0
2
4
Today i am celebrating 5 years since our group moved to @cityofhope. I am grateful to the institution where, despite the pandemic, we secured two R01s + many foundation grants, published >70 papers, opened a dozen new ISTs and found amazing colleagues and collaborators.
2
0
47
Great visit to @MDAndersonNews for Grand rounds. Many thanks to colleagues @PaoloStrati @SairaAhmedMD @Lymphoma_Doc @GreenLymphoLab Chris Flowers and all MDACC lymphoma faculty
2
3
62
.@SWOG S2207 is enrolling patients with relapsed/refractory large B-cell #lymphoma. 3-arm trial adds tazemetostat or zanubrutinib to tafasitamab-lenalidomide. PI: Jennifer Amengual, MD @columbiacancer @ColumbiaMed
https://t.co/EmvMCfbhG6
#LBCL #lymsm #hematology @lymphoma
0
5
18
👉👉👉Excited to share that @HemeReports team (@NitinJainMD @Anand_88_Patel @doctorpemm @KMirza @sanamloghavi) is hosting a Spaces event for #ASH24 updates in #CLL Tuesday, Jan 14, 6.30-7.30pm CST Guest discussants: @DanilovLab @mshadman @calliecoombsmd @dbranderMD @mshadman
1
10
32
This is a very important study led by @NGhoshMD and our lymphoma group at @SWOG. Let’s finally CURE FL!
Follicular #lymphoma with low tumor burden is slow growing. #Clinicaltrial S2308 asks if using the drug #mosunetuzumab as early treatment can keep signs and symptoms of this cancer away for longer. https://t.co/UkQIcfjymn. 1-800-4-CANCER. #lymsm @lymphoma @lymphomahub @LLSusa
0
0
14
Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia. @DanilovLab @cityofhope @ASH_hematology #ASH24 #lymsm #hematology
onclive.com
Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.
0
3
6
Looking forward to this tour-de-force ASH recap
Please add this great @VJHemOnc event to your Jan calendar now so you don't miss it: Post-ASH 2024 CLL highlights webinar
1
0
5
